[1]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129-135.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
　Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):129-135.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
点击复制

磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
39
期数:
2015年第2期
页码:
129-135
栏目:
出版日期:
2015-03-25

文章信息/Info

Title:
Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization
作者:
万绪明;  许祖闪;  侯红军
山东省威海市文登中心医院影像科, 264400
Author(s):
Wan Xuming;  Xu Zushan;  Hou Hongjun
Department of Imaging, Weihai Wendeng Central Hospital, Wendeng 264400, China
关键词:
癌; 肝细胞; 磁共振成像; 表观弥散系数; 经导管肝动脉化疗栓塞术
Keywords:
Carcinoma;  hepatocellular; Magnetic resonance imaging; Apparent diffusion coefficient; Transcatheter arterial chemoembolization
DOI:
10.3760/cma.j.issn.1673-4114.2015.02.006
摘要:
目的 探讨磁共振表观弥散系数(ADC)变化率(即△ADC)在肝细胞肝癌(HCC)单次经导管肝动脉化疗栓塞术(TACE)术后疗效评价中的应用价值。方法 选择48例确诊为中晚期HCC并于TACE术前、术后1个月接受常规CT、MRI扫描以及MRI弥散加权成像和动态增强扫描的患者,建立所有患者的随访数据,随访中以肿瘤出现进展为随访结束点,记录患者治疗后肿瘤无进展生存期(PFS);以TACE术后1个月再次行数字减影血管造影(DSA)的肿瘤染色结果作为"金标准",将病灶按治疗效果分为良好组、中等组及差组3组,并根据各组PFS绘制生存曲线。分别比较△ADC、CT及MRI 3种方法对TACE术后疗效的判定价值,并与"金标准"的一致性进行检验。结果 48例患者共56个病灶纳入分析,以"金标准"评价治疗效果,结果:良好组30个、中等组16个、差组10个,3组间生存曲线差异有统计学意义(χ2=29.89,P<0.01),中位PFS分别为7.5、4.0和1.1个月;TACE术后各组ADC均升高,3组间△ADC差异有统计学意义(F=22.41,P<0.01),且3组间生存曲线差异亦有统计学意义(χ2=26.57,P<0.01),中位PFS分别为7.5、4.6和1.8个月。经Kappa检验,△ADC与"金标准"疗效评价方法具有一致性(Kappa值为0.542,P<0.01);以MRI和CT评价治疗效果,其与"金标准"的一致性较差(Kappa值分别为0.328和0.260,P均<0.05),3组间生存曲线仅MRI评价方法显示差异有统计学意义(χ2=30.623,P<0.01).结论 △ADC能及时、客观地评价TACE治疗效果,对指导患者术后的后续治疗有重要临床意义。
Abstract:
Objective To explore the application value of the change ratio of the apparent diffu-sion coefficient(△ADC) in the therapeutic evaluation of thep at obellular carcinoma(HCC) treated by single transcatheter aaefial chemoembolization(TACE).Methods Forty-eight patients diagnosed with advanced HCC underwent diffusion-weighted imaging, dynamic enhanced MRI, and CT before and one month af-ter TACE.The follow-up data for all selected patients were accumulated, and the disease progression in the follow-up was considered the end point.The progression-free survival of every patient was recorded af-ter TACE.The responses one month after TACE were assessed via digital subtraction angiography, △ADC, MRI, and CT, of which DSA was considered the "gold standard." The groups were divided into three groups:good, middle, and bad.The PFS curves were then plotted.The consistency of the other three evaluation methods with the "gold standard" was evaluated by kappa test.Results Fifty-six lesions were found in 48 patients according to the DSA results, where 30, 16, and 10 lesions belonged to the good, middle, and bad groups, respectively.The survival curves among the 3 groups were statis-tically significant(χ2=29.89, P<0.01), and the median PFSs of the good, middle, and bad groups were 7.5, 4.0, and 1.1 months, respectively.The △ADC results indicated that the ADC values generally in.reased after a single TACE;the △ADC and survi val curves among the 3 groups were also statistically significant(χ2=26.57, P<0.01);the median PFSs for the good, middle, and bad groups were 7.5, 4.6, and 1.8 months, respectively.The kappa test shows that the △ADC was perfectly consistent with the "gold standard"(kappa=0.542, P<0.01), but the MRI and CT were poody consistent with the "gold standard"(Kappa=0.328, 0.260, P<0.05).Only the MRI was statistically significant(χ2=30.623, P<0.01) in the survival curve.Conclusions The △ADC can evaluate the efficacy of TACE timely and objec· tively, and the △ADC is clinically significant in guiding the subsequent treatment after a single TACE.

参考文献/References:

[1] Peng W,Chen Y,Jiang Q,et al.Spatial analysis of hepatocellular carcinoma and socioeconomic status in China from a population-based cancer registry[J].Cancer Epidemiol,2010,34(1):29-33.
[2] Lencioni R,Llovet JM.Modified RECIST(mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1): 52-60.
[3] Koh DM,Collins DJ.Diffusion-weighted MRI in the body:appli-cations and challenges in oncology[J].AJR Am J Roentgenol,2007, 188(6):1622-1635.
[4] Okabe N,Morimoto M,Kondo M,et al.Efficacy of chemoemboliza-lion for recurrent HCC after curative ablation therapy[J].Hepato-gastroenterology,2013,60(123):395-399.
[5] 侯红军,许祖闪,万绪明.动态弥散加权成像对HCC的TACE术疗效评价的临床应用[J].医学影像学杂志,2014,24(3): 395-398.
[6] Georgiades C,Geschwind JF,Harrison N,et al.Lack of response af-ter initial chemoembolization for hepatocellular carcinoma:does it predict failure of subsequent treatment?[J].Radiology,2012,265(1):115-123.
[7] Iwazawa J,Ohue S,Mitani T,et al.Identifying feeding arteries dur-ing TACE of hepatic tumors:comparison of C-arnl CT and digital 135 subtraction angiography[J].AJR Am J Roentgenol,2009,192(4):1057-1063.
[8] Mannelli L,Kim S,Hajdu CH,et al.Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization:diffusion-weighted and contrast-enhanced MRI with histopathologic correla-tion of the explanted liver[J].AIR Am J Roentgenol,2009,193(4):1044-1052.
[9] Bonekamp S,Jolepalem P,Lazo M,et al.Hepatocellular carcino-ma:response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data[J].Radiology,2011,260(3):752-761.
[10] Sun Z,Li G,Ai X,et al.Hepatic and biliary damage after transarte-rial chemoembolization for malignant hepatic tumors:incidence, diagnosis,treatment,outcome and mechanism[J].Crit Rev Oncol Hematol,2011,79(2):164-174.
[11] Dong S,Ye XD,Yuan Z,et al.Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepa-tocellularcarcinoma afterchemoembolization[J].Eur J Radiol,2012, 81(3):472-477.
[12] 尚全良,肖恩华,贺忠,等.肝癌经导管动脉灌注化疗栓塞术疗效的MR扩散加权成像动态研究[J]. 中华放射学杂志,2006,40(3):235-240.
[13] Assumpcao L,Choti M,Pawlik TM,et al.Functional MR imaging as a new paradigm for image guidance[J].Abdom Imasing,2009,34(6):675-685.
[14] Yuan Z,Ye XD,Dong S,et al.Role of magnetic resonance diffu-sion-weighted imaging in evaluating response after chemoemboliza-tion of hepatocellular carcinoma[J].Eur J Radiol,2010,75(1): e9-14.
[15] Mannelli L,Kim S,Hajdu CH,et al.Serial diffusion-weighted MRI in patients with hepatocellular carcinoma:prediction and assess-ment of response to transarterial chemoembolization[J].Preliminary experience.Eur J Radiol,2013,82(4):577-582.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
　Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
　Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[3]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[4]戈畅,梁硕.化疗联合DC-CIK生物治疗非小细胞肺癌的临床价值及CT灌注成像的疗效评价[J].国际放射医学核医学杂志,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
　Ge Chang,Liang Shuo.The clinical value and CT perfusion evaluation in chemotherapy combined with DC-CIK biological treatment of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
[5]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
　HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[6]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
　LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[7]于丽娟,李迎辞,王文志,等.PET-CT及PET-CT结合Lung VCAR软件对非小细胞肺癌肺门区淋巴结的诊断分析[J].国际放射医学核医学杂志,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
　YU Li-juan,LI Ying-ci,WANG Wen-zhi,et al.Value of PET-CT and PET-CT combined with Lung VCAR software in the diagnosis of hilar area lymph nodes of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
[8]刘莉,杨景魁.125I粒子植入治疗非小细胞肺癌的护理及辐射防护[J].国际放射医学核医学杂志,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
　LIU Li,YANG Jing-kui.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
[9]朱晓琳,李强.肝腺瘤的影像诊断现状及进展[J].国际放射医学核医学杂志,2011,35(2):124.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
　ZHU Xiao-lin,LI Qiang.Status and advances in imaging diagnsis of hepatic adenoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):124.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
[10]梁吉祥,柴树德,郑广钧,等.CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效[J].国际放射医学核医学杂志,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
　LIANG Ji-xiang,CHAI Shu-de,ZHENG Guang-jun,et al.CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
[11]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
　Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[12]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
　ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[13]李红兵,陈勇,曾建国,等.肝动脉化疗性栓塞结合Ⅱ期手术切除治疗巨块型外生型肝癌[J].国际放射医学核医学杂志,2010,34(1):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
　LI Hong-bing,CHEN Yong,ZENG Jian-guo,et al.Treatment of massive extrahepatic growing hepatocellular carcinoma with TACE in combination with secondary resection[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
[14]郑磊,李前伟.18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用[J].国际放射医学核医学杂志,2008,32(1):23.
　ZHENG Lei,LI Qian-wei.Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):23.
[15]周云,刘璐,宋进华.经肝动脉灌注90Y微球治疗肝癌的研究进展[J].国际放射医学核医学杂志,2006,30(6):321.
　ZHOU Yun,LIU Lu,SONG Jin-hua.Clinical researched progress of intra-arterial radioembolization with 90Y-glass microspheres for treatment of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):321.
[16]麻广宇,刘家金,徐白萱,等.11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究[J].国际放射医学核医学杂志,2018,(4):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
　Ma Guangyu,Liu Jiajin,Xu Baixuan,et al.Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
[17]赵竞,张占文,马慧,等.PET/CT显像剂18F-氟丙酸在肝癌中的生物学评估[J].国际放射医学核医学杂志,2018,(5):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
　Zhao Jing,Zhang Zhanwen,Ma Hui,et al.Biological evaluation of PET/CT imaging agent 18F-fluoropropionic acid in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
[18]陈佩和,徐文贵,李小凤,等.肝细胞肝癌的葡萄糖代谢机制及在PET显像中的应用价值[J].国际放射医学核医学杂志,2018,(6):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]
　Chen Peihe,Xu Wengui,Li Xiaofeng,et al.Glycometabolism mechanism in hepatocellular carcinoma and its application in PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]

备注/Memo

备注/Memo:
收稿日期:2014-07-13。
通讯作者:万绪明,Email:wanxuming@sina.com
更新日期/Last Update: 1900-01-01